[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594950":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":56,"centralContacts":61,"locations":67,"responsibleParty":87,"collaborators":65,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":65,"eligibilityCriteria":94,"healthyVolunteers":91,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":65,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":111,"overallStatus":70,"whyStopped":65,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ImmunoPET imaging in patients with lung cancers","EXPERIMENTAL","Enrolled lung cancer patients will undergo a Trop2\u002FEpCAM-targeted immunoPET\u002FCT scanning.",[13,14,15,16,17,18],"Drug: [68Ga]Ga-NOTA-T4","Drug: [68Ga]Ga-NOTA-RT4","Drug: [18F]F-RESCA-T4","Drug: [18F]F-RESCA-RT4","Drug: [18F]F-RESCA-EPCD6","Drug: [68Ga]Ga-NOTA-EPCD6",[20,27,33,39,45,51],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","[68Ga]Ga-NOTA-T4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[68Ga\\]Ga-NOTA-T4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-T4 injection.",[9],[26],"[68Ga]T4",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"[68Ga]Ga-NOTA-RT4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[68Ga\\]Ga-NOTA-RT4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-RT4 injection.",[9],[32],"[68Ga]RT4",{"type":21,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"[18F]F-RESCA-T4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[18F\\]F-RESCA-T4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-T4 injection.",[9],[38],"[18F]T4",{"type":21,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"[18F]F-RESCA-RT4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[18F\\]F-RESCA-RT4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RT4 injection.",[9],[44],"[18F]RT4",{"type":21,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"[18F]F-RESCA-EPCD6","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[18F\\]F-RESCA-EPCD6. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-EPCD6 injection.",[9],[50],"[18F]F-EPCD6",{"type":21,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"[68Ga]Ga-NOTA-EPCD6","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[68Ga\\]Ga-NOTA-EPCD6. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-EPCD6 injection.",[9],[50],[57],{"name":58,"affiliation":59,"role":60},"Weijun Wei","Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University","STUDY_CHAIR",[62],{"name":58,"role":63,"phone":64,"phoneExt":65,"email":66},"CONTACT","15000083153",null,"wwei@shsmu.edu.cn",[68],{"facility":69,"status":70,"city":71,"state":65,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"Renji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","200127","China","CN",{"type":76,"coordinates":77},"Point",[78,79],121.45806,31.22222,{"lat":79,"lon":78},[82,83],{"name":58,"role":63,"phone":64,"phoneExt":65,"email":66},{"name":84,"role":63,"phone":85,"phoneExt":65,"email":86},"Wenzhi Jia","18317076979","jwzdata@126.com",{"type":88,"investigatorFullName":65,"investigatorTitle":65,"investigatorAffiliation":65,"oldNameTitle":65,"oldOrganization":65},"SPONSOR","100594950","clinical-application-study-of-petct-for-differential-diagnosis-of-non-small-cell-lung-cancer-100594950",false,"NCT07026110","Clinical Application Study of PET\u002FCT for Differential Diagnosis of Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Imaging studies suspecting non-small cell lung cancer;\n3. Solid lung nodules (≥8 mm in diameter) diagnosed by chest ct, which are subject to 18F-FDG PET\u002FCT and surgical resection\u002Fbiopsy of lung nodules according to the NCCN guideline specifications for NSCLC in the 2024 edition;\n4. Patients or family members agreed to participate in this clinical study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Women during pregnancy and lactation;\n2. Persons with a history of surgery and trauma that significantly affects metabolic distribution and anatomical structure;\n3. Persons with severe other systemic diseases or known hypersensitivity to humanized monoclonal antibody products;\n4. Patient is unable to cooperate in completing the PET\u002FCT examination;\n5. Patient has participated in other clinical studies within the past year that have resulted in radiation exposures in excess of an effective dose of 50 mSv, in addition to the radiation exposures anticipated from participation in this clinical study;\n6. Patient should not participate in this clinical trial in the opinion of the investigator.","ALL","18 Years","80 Years",{"count":99,"type":100},100,"ESTIMATED","INTERVENTIONAL",[103],"NA","This study aims to explore the efficacy of Trop2, EpCAM-specific PET\u002FCT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET\u002FCT examinations and conventional 18F-FDG PET\u002FCT in the diagnosis and differential diagnosis of solid lung nodules.",[106,107,108,109,110],"Lung Cancer","Lung Diseases","Lung Neoplasms","Lung Cancer Metastatic","Lung Inflammation",[112,113,114,115],"Trophoblast cell surface antigen 2 (Trop2)","Epithelial cell adhesion molecule(EpCAM)","ImmunoPET","Lung tumor","2025-06-10",{"date":118,"type":119},"2025-06-18","ACTUAL",{"date":121,"type":119},"2024-12-23",{"date":123,"type":100},"2026-10-31",{"name":5,"class":6},1]